Thermo Fisher Scientific has completed the acquisition of Groupe Novasep’s acquisition of viral vector manufacturing business in Belgium – Henogen for nearly €725 million in cash.

The divested viral vector manufacturing business of Novasep offers contract manufacturing services for vaccines and therapies to biotech firms and large biopharma customers.

Through its two locations in Seneffe and Gosselies, Henogen brings over 7,000 square meters of clinical and commercial manufacturing capacity to Thermo Fisher Scientific.

Established more than two decades ago, Henogen has a workforce of around 400 employees with operational and technical expertise in a range of viral vector classes.  The viral vector manufacturing business has an estimated 2020 revenue of €80 million.

Michel Lagarde – executive vice president of Thermo Fisher Scientific said: “Novasep’s viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally.

“The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America. In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors.

“The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe.”

Henogen will become a part of the pharma services business within the laboratory products and services unit of Thermo Fisher Scientific.

Michel Spagnol – president and CEO of Novasep said: “Thermo Fisher is an outstanding partner for our viral vector business and its future development. Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher.

“Our talented employees will bring deep expertise to an organization that shares our commitment to providing ground-breaking new medicines to patients.”

  Belgium, Groupe Novasep, Henogen, Michel Lagarde, Michel Spagnol, Pharma acquisition news, Thermo Fisher Scientific, viral vector manufacturing